ECM1 Modified HF-MSCs Targeting HSC Attenuate Liver Cirrhosis by Inhibiting the TGF-β/Smad Signaling Pathway

The study demonstrates that ECM1-modified hair follicle-derived mesenchymal stem cells (ECM1-HF-MSCs) can effectively treat liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway, which is crucial in liver fibrosis. Using a mouse model of liver cirrhosis induced by CCl4, the research shows that ECM1-HF-MSCs improve liver function and reduce liver injury more effectively than naïve HF-MSCs. These modified cells migrate to the liver, express hepatocyte-specific markers, and significantly inhibit hepatic stellate cell activation. The findings suggest that ECM1-HF-MSCs offer a promising therapeutic approach for liver cirrhosis through genetic modification.